Table 1 Patient characteristics for subcategories of inflammatory myositis
Clinical attribute | Total patients (n = 30) | Dermatomyositis (n = 18) (60%) | Polymyositis (n = 1) (3.33%) | Immune mediated necrotizing myositis (n = 4) (13.33%) | Overlap myositis (n = 7) (23.33%) |
|---|---|---|---|---|---|
Female: male ratio | 1.73:1 | 1.25:1 | 1:0 | 3:1 | 2.5:1 |
Mean age (years) | 40.33 ± 11.56 | 38.61 ± 10.01 | 45 | 44.75 ± 8.54 | 41.57 ± 17.27 |
Mean duration of illness (months) | 7.3 ± 6.02 | 7.06 ± 6.40 | 12 ± 0 | 5.75 ± 2.5 | 8.14 ± 7.0 |
MSA positive | 21 (70.00) | 15 (83.33) Mi2b = 13 Mi2a = 4 PL7 = 1 PL12 = 1 Tif1gamma = 1 NxP2 = 1 | 4 (100.0) SRP = 4 | 2 (28.57) PL7 = 2 PL12 = 1 | |
MAA positive | 11 (36.67) | 3 (16.67) Ro52 = 4 PM-Scl = 1 PCNA = 1 SS-A = 1 SS-B = 1 | 1 Ro52 = 1 | 2 (50) Ro52 = 2 | 5 (71.43) Ro52 = 5 PM-Scl75 = 1 PM-Scl100 = 1 SS-A = 1 SS-B = 1 |
ANA positive | 8 (26.67) | 3 (16.67) | – | 1(25.00) | 4 (57.14) |
Mean serum CK (units/litre ± SD) | 5398 ± 4677 | 6535 ± 5305 | 3857 ± 0 | 6127 ± 2859 | 2278 ± 2435 |
Mean SGOT (units/litre ± SD) | 187 ± 189 | 232 ± 231 | 158 ± 0 | 171 ± 36 | 87 ± 52 |
Mean SGPT (units/litre ± SD) | 116 ± 80 | 128 ± 90 | 148 ± 0 | 145 ± 41 | 66 ± 57 |
Muscle pain | 25 (83.33) | 16 (88.88) | 1 | 3 (75.00) | 5 (71.43) |
Muscle cramps | 1 (3.33) | 1 (5.56) | – | – | – |
Limb weakness | 30 (100.00) | 18 (100.00) | 1 | 2 (100.0) | 6 (100.0) |
Proximal UL weakness | 20 (66.67) | 11 (61.11) | 1 | 2 (50.00) | 6 (85.71) |
Distal UL weakness | 7 (23.33) | 4 (22.22) | – | – | 3 (42.86) |
Proximal LL weakness | 20 (66.67) | 12 (66.67) | 1 | 2 (50.00) | 5 (71.43) |
Distal LL weakness | 4 (13.33) | 3 (16.67) | – | – | 1 (14.29) |
Truncal weakness | 19 (63.33) | 12 (66.67) | – | 3 (75.00) | 4 (57.14) |
Neck flexor weakness | 22 (73.33) | 16 (88.89) | – | 2 (50.00) | 4 (57.14) |
Neck extensor weakness | 19 (63.33) | 14 (77.78) | – | 2 (50.00) | 3 (42.86) |
Bulbar weakness | 15 (50.00) | 10 (55.56) | 1 | 1 | 3 (42.86) |
Facial weakness | 8 (26.67) | 8 (44.44) | – | – | – |
Respiratory symptoms | 3 (10.00) | 3 (16.67) | – | – | – |
Skin involvement | 23 (76.67) | 16 (88.89) | 0 | 2 (50.00) | 5 (71.43) |
Skin Hyperpigmentation | 19 (63.33) | 13 (72.22) | – | 1 (25.00) | 5 (71.43) |
Photosensitivity | 5 (16.67) | 3 (16.67) | – | – | 2 (28.57) |
Scleroderma | 7 (23.33) | 5 (27.78) | – | – | 2 (28.57) |
Skin ulcers | 1 (3.33) | – | – | – | 1 (14.29) |
Oral ulcers | 1 (3.33) | 1 (5.56) | – | – | – |
Arthralgia | 11 (36.67) | 8 (44.44) | – | 1 | 2 (28.57) |
Weight loss | 15 (50.00) | 9 (50.00) | 1 | 2 (50.00) | 3 (42.86) |
Loss of appetite | 10 (33.33) | 7 (38.89) | 1 | 1 (25.00) | 1 (14.29) |
Muscle wasting | 15 (50.00) | 10 (55.56) | 1 | 1 (25.00) | 3 (42.86) |
Wheel chair bound at evaluation | 14 (46.67) | 9 (50.00) | 1 | 2 (50.00) | 2 (28.57) |